Schizophrenia is a chronic debilitating illness, often with high relapse rates and a chronic course.
| INTRODUC TI ON
Schizophrenia is a chronic debilitating illness, often with high relapse rates and a chronic course. 1 Most patients require long-term treatment with antipsychotic medications. 1 Frequent switching of antipsychotic medications due to lack of efficacy, tolerability and non-adherence issues are common in schizophrenia treatment. 2 Long-acting injectable (LAI) formulations provide an advantage over oral antipsychotics with improved treatment outcomes including improved medication adherence and persistence, lower rates of hospitalisations, and a pharmacokinetic (PK) profile characterised by a prolonged terminal phase that helps delay relapse compared to oral formulations. 3 Paliperidone (9-hydroxyrisperidone) is the major metabolite of risperidone, with a similar serotonin (5HT 2A ) and dopamine (D2) antagonism and receptor binding profile. 4 Patients taking risperidone are therefore exposed as well to paliperidone following in vivo conversion and the clinical effects of oral risperidone result from the combined concentrations of risperidone and paliperidone (ie active-moiety). 5 Paliperidone palmitate is a long-acting injectable formulation of paliperidone that is available in 1-month and 3-month formulations.
The paliperidone palmitate 3-month formulation (PP3M) can be administered after patients are adequately treated and symptomatically stabilised for at least 4 months on the paliperidone palmitate 1-month formulation (PP1M). The corresponding PP3M dose is 3.5 times the maintenance PP1M dose. The corresponding oral paliperidone to PP1M maintenance dose has already been established (PP1M prescribing information). 6 However, data are not available describing corresponding maintenance dose levels of PP1M for patients previously stabilised on oral risperidone. Moreover, to our knowledge, no clinical studies have been performed that provide a direct comparison of steady-state (SS) risperidone and paliperidone exposures following oral risperidone or PP1M administration.
This study aims to assess the dose strengths of PP1M that result in similar SS exposures to the dose strengths of oral risperidone, using PK simulations based on population PK models developed for the two formulations. Population PK techniques provide a unified framework to characterise the PK of a compound by condensing observations from multiple studies while accounting for differences in patient factors and study design. Both short-term and long-term studies utilising sparse and/or rich PK sampling contribute to the understanding of the PK properties. The use of population PK approaches is well accepted and has been advocated by many regulatory agencies including FDA and CHMP. 7, 8 A similar methodology to that described in this work has been applied to derive the dose conversion factor between PP1M and PP3M, 9,10 between oral paliperidone extended-release (ER) or risperidone LAI and PP1M, 11 and between paliperidone ER and PP1M. 6 In this work, we leverage population PK simulations to provide prescribers with practical guidance on PP1M maintenance dosing after transition from oral risperidone.
| ME THODS
To estimate the maintenance dose conversion between formulations, model-based PK simulations were performed using the population PK models of oral risperidone and PP1M, which were developed and validated based on extensive clinical study data, ie 780 patients from 9 studies for risperidone 12 and 1795 patients from 11 trials for PP1M. 13 For oral risperidone, the PK of the active antipsychotic fraction (ie active moiety, risperidone plus paliperidone) was characterised by a first-order absorption process with delay, describing absorption from Injection site (deltoid vs gluteal) was found to influence the absorption process of PP1M (ie slower first-order absorption process for gluteal vs deltoid site; higher fraction of dose absorbed via the "fast" zero-order process for deltoid vs gluteal site), which is likely due to different distribution of muscle and adipose tissues in the 2 injection sites. Additional covariate effects have been described elsewhere. 13 Paliperidone is not significantly metabolised by the CYP2D6 enzyme and hence is also not impacted by this genotype.
The population PK models described above were used to simulate SS PK profiles according to the following dosing regimens:
• Oral risperidone once-daily at doses of 1, 2, 3, 4, and 6 mg;
• PP1M every 4 weeks (deltoid or gluteal injections) at doses of 25, 50, 75, 100, and 150 mg equivalents (mg eq.) of paliperidone (the corresponding doses of paliperidone palmitate substance are 39, 78, 117, 156, and 234 mg, respectively; the conversion factor from mg eq. to mg is 1.56). Initiation with deltoid injections of 150 mg eq.
(234 mg) on day 1 and 100 mg eq. (156 mg) on day 8 was simulated.
Similarity between given doses of oral risperidone and PP1M
was assessed via graphical evaluation of central tendency and variability in the population as median and 90% prediction interval of 
What's new
• This study provides clinicians with a practical guidance to establish suitable maintenance dose levels of PP1M and oral risperidone when transitioning patients from one formulation to another. 1000 simulated individual PK profiles for each formulation. Since the primary purpose of this analysis was to establish dose conversion factors between the two drugs for maintenance treatment (when PK SS can be assumed), the simulated PK profiles were depicted over a hypothetical time frame of 28 days at SS. Paliperidone concentrations following PP1M administration were overlaid on active-moiety concentrations following oral risperidone administration to enable graphical comparison of the whole SS PK profile.
| RE SULTS
The PP1M maintenance doses of 25, 50, 75, 100 and 150 mg eq.
(injected either in the deltoid or gluteus) are expected to result in similar SS exposure range (based on median and 90% prediction interval) to oral risperidone doses of 1, 2, 3, 4, and 6 mg oncedaily, respectively, which results in a 25-fold dose conversion factor from oral risperidone to PP1M. Because the PK of the active moiety following oral risperidone treatment is linear, 12 administering the same total daily dose in a twice-daily regimen (eg 6 mg/d administered as 3 mg twice-daily) is only expected to result in a reduced peak-trough ratio, compared to a once-daily regimen. The average plasma concentration over the dosing interval is not affected. Therefore, the above dose conversion results can be assumed to hold also for oral risperidone administered twice-daily for the same total daily dose.
| D ISCUSS I ON
This work describes the exposure-matching between oral risperidone and paliperidone palmitate dose levels based on PK similarity at SS, using population PK simulations. Population PK approaches provide a comprehensive framework to characterise the PK of a compound from multiple studies while accounting for inter-subject variability. 6 Once treatment with PP1M has been initiated (ie on day 1), oral antipsychotics can be discontinued. 6, 11, 18 Clinical factors related to adherence, efficacy and tolerability are critically important when establishing a suitable maintenance dose 
| CON CLUS ION
This analysis provides the clinician with a practical guidance to establish suitable maintenance dose levels of PP1M and oral risperidone when transitioning patients from one formulation to another, such that SS active-moiety exposures are similar between the two drugs. In addition to PK considerations, clinical symptoms should always be considered when switching medications. Patients undergoing a switch should be monitored closely before and after switching the medications. 
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